Jazz Pharmaceuticals Announces Initiation of Phase 3 Trial Evaluating Epidiolex®/Epidyolex® (cannabidiol) for Patients with Epilepsy with Myoclonic-Atonic Seizures
/PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced it has initiated a new Phase 3 trial to investigate the efficacy and safety of...
Source: prnewswire.com